Novo Nordisk Gets Approval For Hemophilia B Treatment Sans Postmarketing Requirements

Rebinyn's approval without postmarketing requirements comes as a surprise, given the advisory committee's concerns that the proposed plans weren't robust enough, as well as concerns from FDA about the treatment's safety.